TY - JOUR
T1 - Del (9q) AML: clinical and cytological characteristics and prognostic implications
AU - Peniket, A
AU - Wainscoat, J
AU - Side, L
AU - Daly, S
AU - Kusec, R
AU - Buck, G
AU - Wheatley, Keith
AU - Walker, H
AU - Chatters, S
AU - Harrison, C
AU - Boultwood, J
AU - Goldstone, A
AU - Burnett, A
PY - 2005/4/1
Y1 - 2005/4/1
N2 - Del (9q) is a recurrent cytogenetic abnormality in acute myeloid leukaemia (AML). We report an analysis of 81 patients with del(9q) as a diagnostic karyotypic abnormality entered into the Medical Research Council AML trials 10, 11 and 12. Patients were divided into three groups: (i) Sole del (9q), 21 patients; (ii) Del(9q) in association with t(8;21), 29 patients; (iii) Del(9q) in association with other cytogenetic abnormalities, 31 patients. Sole del(9q) was associated with a characteristic bone marrow phenotype at diagnosis: a single Auer rod was found in all cases examined. There was also an association with erythroid dysplasia (74%) and granylocytic lineage vacuolation (90%). The incidence of all three of these features was significantly higher (P <0.05) in the sole del(9q) group compared with control cases lacking del(9q). The overall survival (OS) of all 81 patients was compared with a control group of 1738 patients with normal cytogenetics entered in the same trials over the period of investigation. The 5-year OS for patients with del(9q) was 45%, compared with 35% for the control group (P = 0.09). Patients with del(9q) in association with t(8;21) had a 5-year OS of 75%, which was significantly better than the groups with either sole del(9q) (40%) and del(9q) with other abnormalities (26%; P = 0.008). Karyotyping indicated a common area of deletion in the region 9q21-22, which was present in 94% of cases. It is likely that the deletion of single or multiple tumour suppressor genes located in this region may underlie the pathogenesis of del (9q) AML.
AB - Del (9q) is a recurrent cytogenetic abnormality in acute myeloid leukaemia (AML). We report an analysis of 81 patients with del(9q) as a diagnostic karyotypic abnormality entered into the Medical Research Council AML trials 10, 11 and 12. Patients were divided into three groups: (i) Sole del (9q), 21 patients; (ii) Del(9q) in association with t(8;21), 29 patients; (iii) Del(9q) in association with other cytogenetic abnormalities, 31 patients. Sole del(9q) was associated with a characteristic bone marrow phenotype at diagnosis: a single Auer rod was found in all cases examined. There was also an association with erythroid dysplasia (74%) and granylocytic lineage vacuolation (90%). The incidence of all three of these features was significantly higher (P <0.05) in the sole del(9q) group compared with control cases lacking del(9q). The overall survival (OS) of all 81 patients was compared with a control group of 1738 patients with normal cytogenetics entered in the same trials over the period of investigation. The 5-year OS for patients with del(9q) was 45%, compared with 35% for the control group (P = 0.09). Patients with del(9q) in association with t(8;21) had a 5-year OS of 75%, which was significantly better than the groups with either sole del(9q) (40%) and del(9q) with other abnormalities (26%; P = 0.008). Karyotyping indicated a common area of deletion in the region 9q21-22, which was present in 94% of cases. It is likely that the deletion of single or multiple tumour suppressor genes located in this region may underlie the pathogenesis of del (9q) AML.
KW - acute myeloid leukaemia
KW - cytogenetics of leukaemia
UR - http://www.scopus.com/inward/record.url?scp=20244386716&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2005.05445.x
DO - 10.1111/j.1365-2141.2005.05445.x
M3 - Article
C2 - 15813849
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
SN - 1365-2141
VL - 129
SP - 210
EP - 220
JO - British Journal of Haematology
JF - British Journal of Haematology
ER -